Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Group 1 - Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS) [1][2] - The company will report its financial results for the first quarter ended March 31, 2025, and host a corporate update conference call on May 15, 2025, at 8:30 AM Eastern Time [1] - Taysha's lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies [2] Group 2 - The management team of Taysha has proven experience in gene therapy development and commercialization [2] - The company aims to address severe unmet medical needs and improve the lives of patients and their caregivers through transformative medicines [2] - Taysha leverages its manufacturing process and a clinically and commercially proven AAV9 capsid to translate treatments from bench to bedside [2]